AbbVie Seeks FDA's Green Light for Pivekimab Sunirine in BPDCN Treatment AbbVie has submitted a Biologics License Application for Pivekimab sunirine, aimed at treating patients with the rare blood cancer BPDCN, providing hope where treatment options are limited.

AbbVie Seeks FDA's Green Light for Pivekimab Sunirine in BPDCN Treatment #United_States #AbbVie #North_Chicago #BPDCN #Pivekimab_Sunirine